fam med
Quiz yourself by thinking what should be in
each of the black spaces below before clicking
on it to display the answer.
Help!
|
|
||||
---|---|---|---|---|---|
what are the 6 stages of behavior change | precontemplation, contemplation, determination, action, maintenance, relapse
🗑
|
||||
3 MC causes of dyspepsia | GERD, PUD, fxnl dyspepsia (diagnose after upper endoscopy, etc are all nml)
🗑
|
||||
alarm symptoms in dyspepsia | age>55 w new onset of sympt, FMH of upper GI cancer, wgt loss, bleeding, worsening dysphagia, odynophagia, anemia, persistent vomitting
🗑
|
||||
remember to ask abt NSAID use in dyspepsia |
🗑
|
||||
mgmt GERD | PPI, if taking NSAID need to stop (I guess don't need PPI)
🗑
|
||||
if dyspepsia but not GERD or NSAID, how manage? | can do empiric PPI or H2 antagonist; **(best) H Pylori test/treat; endoscopy
🗑
|
||||
lifestyle changes for GERD& dyspepsia | just avoid trigger foods if only dyspepsia, if GERD: wgt loss, elevating head of bed, avoiding spicy and large meals and meals before bed
🗑
|
||||
triple tx for H Pylori | PPI, clarithromycin, amox (flagyl if allergic to PCN)
🗑
|
||||
on female w UTI sympt be sure to ask abt | gyne symptoms (discharge, pelvic pain) and even menstrual history; sympt suggestive of pyelo (F/C, N/V, back pain)
🗑
|
||||
serious UTI type diseases want to consider/ r/o | renal cell or bladder cancer, pyelo, PID, nephrolithiasis
🗑
|
||||
ppl at risk for complicated UTI (ie pyelo) | fxnl or anatomic abnlty of urinary tract incl polycystic kidney dz, nephrolithiasis, neurogenic bladder, preg, DM or immunosupp, recent urinary tract procedure or catheter
🗑
|
||||
lifestyle changes for UTI | liquids, urinate s/p sex, drink cranberry juice, wipe front to back s/p BM
🗑
|
||||
MC bugs for UTI in female | E Coli, then Staph Sapro
🗑
|
||||
tx for uncomplicated UTI in women | 3d Bactrim or Cipro sufficient, if recurrent may used 5-10d and ensure infxn clears
🗑
|
||||
what cxns or serious URI don't want to miss | meningitis, brain abscess, orbital cellulitis
🗑
|
||||
imaging/w/u for URI/sinusitis | none, could order sinus XR or CT, but not usu helpful, sinus cx could be considered if resistant to tx
🗑
|
||||
tx URI/sinusitis | if just viral use nasal saline spray, can give nasal decongestant (pseudoephed, oxymetazoline 3-5d), if sinusitis amox
🗑
|
||||
if allergic component URI how tx | loratadine (claritin), fexofenadine (allegra)
🗑
|
||||
mild persistent asthma symptoms and use of inhaler | daytime symptoms (using b2) >2x/wk, nighttime 3-4/mo, FEV1 >80% and FEV1/FVC nml (same as intermittent)
🗑
|
||||
levels of asthma | intermittent, mild persistent, moderate persistent, severe persistent
🗑
|
||||
moderate persistent asthma symptoms and use of inhaler | daytime symptoms (using b2) everyday, nighttime sympt >1x/wk, FEV1 60-80% and FEV1/FVC reduced by 5%
🗑
|
||||
severe persistent asthma symptoms and use of inhaler | daytime symptoms (using b2) throughout the day, nighttime sympt every night, FEV1 <60% and FEV1/FVC reduced by >5%
🗑
|
||||
well controlled asthma | sympt <2x/wk and nighttime <2x/mo, no interference nml activity, FEV1 >80% of best (can f/u 6mos)
🗑
|
||||
not well controlled asthma | sympt >2x/wk and nighttime >2x/mo, some limitation nml activity, FEV1 60-80% of best (add tx and f/u 2-6wks)
🗑
|
||||
poor controlled asthma | sympt throughout the day, nighttime sympt almost every night, using b2 mltpl times/day, FEV<60%, for tx consider short term oral steroids and f/u 2wks
🗑
|
||||
SE of b2 | tachycardia, tremor, hypoK, paradoxical bronchospasm
🗑
|
||||
SE ipratropium | antichol, ie dry mouth, nervous, can have anaphylactic rxn, angioedema
🗑
|
||||
SE mast cell stabilizer (cromolyn) | throat irritation/dry throat, bronchospasm, anaphylaxis
🗑
|
||||
SE theophylline | N/V, HA, insomnia, irritability. Serious SE: arrhythmias, sz
🗑
|
||||
SE leukotriene modifiers | various incl HA, flu like/URI, GI sympt. Serious SE incl angioedema, anaphylaxis
🗑
|
||||
mech of action theophylline | prevents breakdown of cAMP and cGMP for sm mscl relax and bronchodilation, also inhibits inflamm mediators
🗑
|
||||
key adv/disadv theophylline | cost is advantage; disadv incl SE and need to monitor levels
🗑
|
||||
comorbidities/triggers asthma | allergens, GERD, allergic rhinitis, smoke exposure, obesity and OSA
🗑
|
||||
components to developing therapeutic relationship | develop atmosphere of trust, connect on non-medical topic, learn abt family contextual things related to dz, offer to partner w pt, show empathy, etc
🗑
|
||||
tx for mild persistent? Moderate? Severe? | short acting b2 + low dose steroid. For moderate add long acting b2. for severe add medium dose steroid--if that doesn't control add oral steroid
🗑
|
||||
cut offs for lipids | tChol <200, >240 is high. TG <150, >200 high. HDL 40-60 (where 60 or higher is good!). LDL >160 high
🗑
|
||||
LDL when start tx and goals: pt with BOTH DM and CAD | start lifestyle and Rx at 70, goal <70
🗑
|
||||
LDL when start tx and goals: pt with DM OR CAD OR 10yr risk >20% | start lifestyle at 100 and Rx at 100 or 130, goal <100
🗑
|
||||
LDL when start tx and goals: pt with 2 RF, 10yr risk 10-20% | start lifestyle at 130 and Rx at 100 or 130, goal <130
🗑
|
||||
LDL when start tx and goals: pt with 2 RF, 10yr risk <10% | start lifestyle at 130 and Rx at 160, goal <130
🗑
|
||||
LDL when start tx and goals: pt with <2 RF | start lifestyle at 160 and Rx at 160 or 190, goal <160
🗑
|
||||
RF used to calculate LDL | smoking, HTN, FMH of premature CAD
🗑
|
||||
LDL cutoff and goal for HTN, smoker w/o FMH premature CAD | would need to calculate 10yr risk, but if >20%: start lifestyle at 130 and Rx at 100 or 130, goal <130
🗑
|
||||
SE sulfonylureas | hypoglycemia, wgt gain, rare: hepatitis, heme abnlties
🗑
|
||||
name types of hypolgycemics used DM2 (8, incl 4 MC) | **sulfonylureas (glyburide, glipizide), **biguanides (metformin), **thiazolidinediones (rosiglitazone, pioglitazone),**alpha glucosidase inhibitors (acarbose), meglinitinides, amylin analogs, incretin analogs, DPPV-IV inhibitors
🗑
|
||||
key SE/cautions of metformin | GILMAR=GI, lactic acidosis, metallic taste, renal (can't use if Cr 1.5 male, 1.4 female), wgt loss
🗑
|
||||
which hypoglycemics can cause hepatitis/hepatotoxicity | sulfonylureas, alpha glucosidase, thiazolidinediones
🗑
|
||||
SE meglitinides | hypolgycemia, anaphylactoid, heme
🗑
|
||||
which oral hypoglycemics have risk of hypoglycemia (4) | sulfonylureas, meglitinides, amylin analogs and incretin mimetics
🗑
|
||||
SE thiazolidinediones (rosglitazone, pioglitazone) | fluid retention, hepatotoxicity, CHF
🗑
|
||||
SE alpha glucosidase inhibitors | diarrhea, flatulence, bloating, rare: hypersensitivity, hepatitis
🗑
|
||||
SE amylin analogs | N/V, anorexia, HA, interferes w absorption oral meds, avoid in gastropoeresis, **severe hypoglycemia in DM1
🗑
|
||||
SE incretin mimetics | N/V, diarrhea, avoid in gastropoeresis or severe RF, **severe hypoglycemia in DM2 on sulfonylureas
🗑
|
||||
which oral hypoglycemics have GI SE (4) | **biguanides (metformin), **alpha glucosidase inhibitors (acarbose), amylin analogs, incretin analogs
🗑
|
||||
SE DPPIV inhibitors | runny nose, sore throat, HA, rare: hypersensitivity/anaphylactoid, S-J
🗑
|
||||
MOA sulfonylureas (glyburide, glipizide) | stimulate insulin sxn
🗑
|
||||
adv/disadv sulfonylureas (glyburide, glipizide) | cost, safety, low SE
🗑
|
||||
MOA biguanide (metformin) | incrs insulin sensitivity, decrs liver production of glu
🗑
|
||||
adv/disadv metformin | use in overwgt to decs wgt
🗑
|
||||
MOA meglitinides | pancreas incrsd sxn of insulin (Same as sulfonylureas but shorter acting)
🗑
|
||||
adv/disadv meglitinides | shorter acting than sulfonylureas (meal adjusted dosing), more effective than sulfonylureas and less likely hypoglycemia
🗑
|
||||
MOA thiazolidinediones | enhances insulin sensitivity in mscl
🗑
|
||||
adv/disadv thiazolidinediones | lowers insulin requirements (bc improves insulin sensitivity)
🗑
|
||||
MOA alpha glucosidase inhibitors | inhibits intestinal alpha glucosidase
🗑
|
||||
adv/disadv alpha glucosidase inhib | improves post-prandial hypergly, generally poorly tolerated
🗑
|
||||
MOA amylin analogs, how given | subQ before meal for ppl on insulin. Slows gastric emptying and decrses appetite
🗑
|
||||
adv/disadv amylin analgos | can only use in DM1 or 2 on insulin, improves postprandial hypergly, helps wgt loss, can't give gastropoeresis
🗑
|
||||
MOA incretin mimetics | subQ before meal for DM2. Slows gastric emptying and decrses appetite, stimulates glu dependent insulin secretion
🗑
|
||||
adv/disadv incretin mimetics | improves postprandial hypergly, helps wgt loss
🗑
|
||||
MOA DPPIV inhibitors | incrsd insulin sxn
🗑
|
||||
agents for HLD (5) | bile acid sequest, niacin, statins, fibric acid, ezetimibe
🗑
|
||||
SE bile acid sequest (cholestyramine, colestipol) | GI
🗑
|
||||
SE niacin | flushing, GI, hyperuric; hepatotoxic, PUD, severe hypergly
🗑
|
||||
SE statins | incrsd LFTs, myositis, rhabdo
🗑
|
||||
SE fibric acid derivatives (gemfibrozil, fenofibrate) | GI, incrsd LFTs, gallstones, myositis
🗑
|
||||
SE ezetimibe | upper respir sympt, HA, myalgia, rare hypersensitivity
🗑
|
||||
MOA bile acid sequest | interrupts bile absorb so more cholesterol turned into bile acids in liver
🗑
|
||||
adv/disadv bile acid sequest | usu add to statin bc SE
🗑
|
||||
MOA niacin | decrses TG synthesis in liver and increases lipases clearing vLDL
🗑
|
||||
adv/disadv niacin | good for incrsd TG and LDL, but SE limit use
🗑
|
||||
MOA statin | HMG CoA reductase leading to decrsd cholesterol synthesis in liver
🗑
|
||||
adv/disadv statin | effective and limited SE
🗑
|
||||
MOA fibric acid | binds PPAR
🗑
|
||||
adv/disadv fibric acid | use for high TG
🗑
|
||||
MOA ezetimibe | inhibits cholesterol absorption in small intestine
🗑
|
||||
goals for DM for glu (fasting/postprandial), HbA1c, BP, LDL, TG | fasting glu 130, postprandial 180, BP 130/75, LDL 100, TG 150, HbA1c 7
🗑
|
||||
cut offs for impaired glu tolerance | fasting 110-125 or 2hr postprandial 140-200
🗑
|
||||
cut offs for dx of DM, incl HbA1c | fasting >125 or 2hr postprandial >200, or random >200 w symptoms. Need 2 readings. Or HbA1c >6.5 x2.
🗑
|
||||
ranges for HTN, preHTN | preHTN 120-139/80-89; HTN I: 140-159/90-99; HTN II 160/100
🗑
|
||||
8 meds for HTN | diuretics, bb, ccb, ACEI, ARB, alpha1 antagonists, alpha2 agonists, direct vasodilators
🗑
|
||||
SE BB | FARSHILD: fatigue, asthma, reynauds/impaired peripheral circulation, sex dysfxn, halluc, insomnia, lipid…bradycardia, mask hypoglycemia
🗑
|
||||
SE diuretics | depends on specific, but hypoK, hypoMg, hyperuric, shortterm incrs cholesterol and glu
🗑
|
||||
SE CCBs | HA, flushing, peripheral edema, gingival hyperplasia, constipation, bardycardia/arrhythmias, CHF (ie verapamil ChOPPd Liver: constip, heart block, prolactin, potassium)
🗑
|
||||
SE ACEI | CAPTOPRIL: cough, angioedema, potassium, taste, preg, rash, liver toxicity
🗑
|
||||
SE ARB | angioedema (less than ACEI), hyperK
🗑
|
||||
SE alpha1 blockers | orthostatic hypotension
🗑
|
||||
SE a2 agonist | antichol, ie sedataion, dry mouth, bradycardia, rebound HTN
🗑
|
||||
SE vasodilators | HA, flushing, reflex tachycardia, lupus like
🗑
|
||||
ex of direct vasodilators | hydralazine, NG, nitroprusside, isosorbide nitrate
🗑
|
||||
ex of central alpha 2 agonists | methyldopa, clonidine
🗑
|
||||
MOA alpha1 blocker | blocks post syn alpha1, leads to less NE release
🗑
|
||||
adv/disadv direct vasodilators | difficult to control HTN, rapid control via IV, also pregnancy (hydralazine)
🗑
|
||||
adv/disadv diuretics for HTN | CHF
🗑
|
||||
adv/disadv bb for HTN | post MI, angina, SVT, CHF, diastolic dysfxn, migraine
🗑
|
||||
adv/disadv ccb for HTN | angina, SVT, reynauds, diastolic dysfxn, migraine
🗑
|
||||
adv/disadv ACEI for HTN | DM w albuminuria, CHF, postMI w systolic dysfxn, prevention progression CRF
🗑
|
||||
adv/disadv alpha1 blockers for HTN | BPH, HLD
🗑
|
||||
adv/disadv alpha2 agonist for HTN | clonidine can be used for rapid control HTN
🗑
|
||||
what's BATHE model for psych visits | Background (what's happening), affect (emotl state), trbl (what trbles you most), handling, empathy
🗑
|
||||
in prevention and screening what are the 6 major areas | CV, cancer, ID, injury/trauma, metabolic, emotl
🗑
|
||||
screening DM starts, freq | 45yo q3yrs or overwgt other RF
🗑
|
||||
screening HLD starts, freq | 35men, 45 women, q5
🗑
|
||||
DEXA starts | 65yo, 60 if high risk
🗑
|
||||
mammography starts, freq | 50-75 q2
🗑
|
||||
colonoscopy starts, freq | 50yo q10, or 10yrs before earliest/40yo high risk
🗑
|
||||
ASA given to | 45-79men and 55-79yo women for DM and hi risk CVD
🗑
|
||||
pap smear starts, freq | 21-30 q2; 30-65 q3
🗑
|
||||
pelvic starts, freq | 20-40 q3; annual >40
🗑
|
Review the information in the table. When you are ready to quiz yourself you can hide individual columns or the entire table. Then you can click on the empty cells to reveal the answer. Try to recall what will be displayed before clicking the empty cell.
To hide a column, click on the column name.
To hide the entire table, click on the "Hide All" button.
You may also shuffle the rows of the table by clicking on the "Shuffle" button.
Or sort by any of the columns using the down arrow next to any column heading.
If you know all the data on any row, you can temporarily remove it by tapping the trash can to the right of the row.
To hide a column, click on the column name.
To hide the entire table, click on the "Hide All" button.
You may also shuffle the rows of the table by clicking on the "Shuffle" button.
Or sort by any of the columns using the down arrow next to any column heading.
If you know all the data on any row, you can temporarily remove it by tapping the trash can to the right of the row.
Embed Code - If you would like this activity on your web page, copy the script below and paste it into your web page.
Normal Size Small Size show me how
Normal Size Small Size show me how
Created by:
ehstephns
Popular Midwifery sets